For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Novavax, Inc (NASDAQ: NVAX) was $7.1 for the day, up 0.85% from the previous closing price of $7.04. In other words, the price has increased by $0.85 from its previous closing price. On the day, 2.95 million shares were traded. NVAX stock price reached its highest trading level at $7.16 during the session, while it also had its lowest trading level at $7.01.
Ratios:
Our analysis of NVAX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.03 and its Current Ratio is at 2.06.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on June 17, 2025, initiated with a Sell rating and assigned the stock a target price of $6.
On February 28, 2025, BTIG Research started tracking the stock assigning a Buy rating and target price of $19.
JP Morgan Downgraded its Neutral to Underweight on July 30, 2024, while the target price for the stock was maintained at $8.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 19 ’25 when YOUNG JAMES F bought 10,000 shares for $7.59 per share.
YOUNG JAMES F bought 4,000 shares of NVAX for $24,406 on Apr 14 ’25. On Dec 13 ’24, another insider, King Rachel K., who serves as the Director of the company, sold 4,150 shares for $9.02 each. As a result, the insider received 37,435 and left with 14,770 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVAX now has a Market Capitalization of 1159792128 and an Enterprise Value of 517593120. As of this moment, Novavax,’s Price-to-Earnings (P/E) ratio for their current fiscal year is 2.68, and their Forward P/E ratio for the next fiscal year is 31.29. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.92. Its current Enterprise Value per Revenue stands at 0.412 whereas that against EBITDA is 1.107.
Stock Price History:
The Beta on a monthly basis for NVAX is 2.50, which has changed by -0.45842868 over the last 52 weeks, in comparison to a change of 0.11844492 over the same period for the S&P500. Over the past 52 weeks, NVAX has reached a high of $17.81, while it has fallen to a 52-week low of $5.01. The 50-Day Moving Average of the stock is 4.85%, while the 200-Day Moving Average is calculated to be -14.48%.
Shares Statistics:
NVAX traded an average of 8.80M shares per day over the past three months and 4358250 shares per day over the past ten days. A total of 161.96M shares are outstanding, with a floating share count of 147.54M. Insiders hold about 8.91% of the company’s shares, while institutions hold 56.79% stake in the company. Shares short for NVAX as of 1749772800 were 44482397 with a Short Ratio of 5.06, compared to 1747267200 on 46467707. Therefore, it implies a Short% of Shares Outstanding of 44482397 and a Short% of Float of 27.560000000000002.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Investors are eagerly awaiting the insights provided by 5.0 analysts currently analyzing and rating the stock of Novavax, Inc (NVAX).The consensus estimate for the next quarter is -$0.24, with high estimates of $0.31 and low estimates of -$0.7.
Analysts are recommending an EPS of between $3.54 and $1.19 for the fiscal current year, implying an average EPS of $2.56. EPS for the following year is $0.31, with 6.0 analysts recommending between $2.69 and -$1.3.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 5 analysts. It ranges from a high estimate of $200.27M to a low estimate of $68.5M. As of the current estimate, Novavax, Inc’s year-ago sales were $415.48MFor the next quarter, 5 analysts are estimating revenue of $100.95M. There is a high estimate of $234M for the next quarter, whereas the lowest estimate is $32.77M.
A total of 6 analysts have provided revenue estimates for NVAX’s current fiscal year. The highest revenue estimate was $1.26B, while the lowest revenue estimate was $836.8M, resulting in an average revenue estimate of $1.02B. In the same quarter a year ago, actual revenue was $682.16MBased on 6 analysts’ estimates, the company’s revenue will be $527.27M in the next fiscal year. The high estimate is $996.5M and the low estimate is $324M.
